ReviewClinical pharmacology and therapeutics2012
Novel data-mining methodologies for adverse drug event discovery and analysis.
Review in Clinical pharmacology and therapeutics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 195 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
195 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Computational Advances in Drug Safety: Systematic and Mapping Review of Knowledge Engineering Based Approaches.Frontiers in pharmacology · 2019Pooled it
- Pooled it
- CAFNet-DG: Task-Specific Modeling and Prevalence-Aware Evaluation for Adverse Drug Reaction Prioritization with Ordinal-Frequency Estimation.International journal of molecular sciences · 2026Article
- Thrombotic and ischemic event reporting with anticoagulant reversal agents: a multi-agent FAERS pharmacovigilance study.Journal of thrombosis and thrombolysis · 2026Article
- Quarterly persistence as a signal prioritization framework in FAERS: an analysis of the 2025 public-use releases.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Pharmacovigilance Analysis of Drug-Induced Stomatitis: Insights From Twenty-One Years of Real-World Data.International dental journal · 2026Article
- Patient-Level Risk Characterization of Drug-Associated Hidradenitis Suppurativa Using Machine Learning.medRxiv : the preprint server for health sciences · 2026Article
- The association between colorectal cancer drugs and heart failure: a real-world pharmacovigilance study of the FAERS database.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Mapping adverse events and monitoring priorities for trastuzumab deruxtecan use in metastatic breast cancer.International journal of surgery (London, England) · 2026Article
- Computational pharmacovigilance of Lifitegrast in dry eye disease using machine learning and network toxicology.NPJ digital medicine · 2026Article
- Pharmacovigilance-Based Identification and Mechanistic Exploration of Periodontitis-Related Drugs.Journal of clinical periodontology · 2026Article
- Hand-foot skin reaction associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a FAERS-based pharmacovigilance study.Frontiers in medicine · 2026Article
- Development and validation of a MedDRA-based signal detection construct for drug-induced neurobehavioral impairment.Therapeutic advances in drug safety · 2026Article
- Early post-marketing safety profile of resmetirom in FAERS: an exploratory assessment of statin co-reporting.Frontiers in pharmacology · 2026Article
- MSAT: a FAERS-informed heterogeneous graph neural network for pharmacovigilance prediction of Chinese materia medica-associated adverse drug reactions.Frontiers in pharmacology · 2026Article
- Absence of pharmacovigilance signals for bleeding events associated with warfarin-SSRI drug interactions: a comparative analysis of FAERS and CVARD databases.Therapeutic advances in drug safety · 2026Article
- Post-marketing safety surveillance and signal characterization of the novel dissociative steroid Vamorolone in Duchenne muscular dystrophy: a comparative disproportionality analysis based on FAERS data.Frontiers in pharmacology · 2026Article
- Antibiotic-associated adverse events in bone and joint infections: a FAERS pharmacovigilance study.Frontiers in medicine · 2026Article
- Risk of diabetes mellitus with olanzapine compared to clozapine: A systematic review and meta-analysis.PCN reports : psychiatry and clinical neurosciences · 2025Article
- Pharmacovigilance assessment of drug-induced aplastic anemia: analysis of the FDA adverse event reporting system.International journal of clinical pharmacy · 2025Article
135 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
An important goal of the health system is to identify new adverse drug events (ADEs) in the postapproval period. Datamining methods that can transform data into meaningful knowledge to inform patient safety have proven essential for this purpose. New opportunities have emerged to harness data sources that have not been used within the traditional framework. This article provides an overview of recent methodological innovations and data sources used to support ADE discovery and analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.